ATIM-49 - AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BiTE^®) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (rGBM)

Saturday, November 23

5:00 PM - 7:00 PM

Location: Ballroom Lawn

Poster Presenting Author(s)

CB

Carmen Balana

Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol
Mv

Myra van Linde

VU Medical Center
CS

Cyrus Sayehli

University of Würzburg
WF

Walter Fiedler

University Medical Center Hamburg-Eppendorf
MW

Martin Wermke

University Cancer Center Dresden
CM

Christophe Massard

Gustave Roussy
IM

Ingo Mellinghoff

Memorial Sloan Kettering Cancer Center
Mustafa Khasraw

Neurooncologist
Duke University
AA

Agnes Ang

Amgen Inc.
ER

Erik Rasmussen

Amgen Inc.
JK

Johannes Kast

Amgen Inc.
SS

Sabine Stienen

Amgen Inc
Timothy Cloughesy

Professor
University of California Los Angeles